Cardiff Oncology’s onvansertib shows efficacy in Phase 2 colorectal cancer trial

cafead

Administrator
Staff member
  • cafead   Dec 10, 2024 at 11:52: AM
via Cardiff Oncology (CRDF) announced positive initial data from CRDF-004, a randomized, Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care in patients with first-line RAS-mutated metastatic colorectal cancer, or mCRC.

article source